Lynx1 Capital Management LP C4 Therapeutics, Inc. Transaction History
Lynx1 Capital Management LP
- $270 Million
- Q1 2025
A detailed history of Lynx1 Capital Management LP transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Lynx1 Capital Management LP holds 7,098,133 shares of CCCC stock, worth $11 Million. This represents 4.2% of its overall portfolio holdings.
Number of Shares
7,098,133
Previous 6,852,744
3.58%
Holding current value
$11 Million
Previous $24.7 Million
53.96%
% of portfolio
4.2%
Previous 9.58%
Shares
7 transactions
Others Institutions Holding CCCC
# of Institutions
118Shares Held
63.1MCall Options Held
18.8KPut Options Held
0-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$10.8 Million0.92% of portfolio
-
Orbimed Advisors LLC San Diego, CA6.83MShares$10.6 Million0.34% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.72MShares$10.4 Million0.06% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$7.05 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.05MShares$6.27 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $75.8M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...